Phase II dose finding trial of oral testosterone undecanoate [LPCN 1021] in hypogonadal men

Trial Profile

Phase II dose finding trial of oral testosterone undecanoate [LPCN 1021] in hypogonadal men

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2014

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Feb 2014 New trial record
    • 10 Feb 2014 The starting dose selected for the phase III SOAR trial was selected based on results of this trial (primary endpoint met and no significant adverse events), according to a Lipocine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top